Omeprazole
Proton pump inhibitors (PPIs) such as omeprazole and lansoprazole inhibit the production of gastric acid.
They are the drugs of choice for patients with significant erosive oesophagitis and for patients with Zollinger- Ellinson syndrome.
The NICE guideline concerning the management of dyspepsia in primary care suggests PPIs as first-line therapies in non-ulcer dyspepsia, gastro-oesophageal reflux disease and peptic ulcer disease (see linked NICE dyspepsia guideline).
Related pages
- Indications
- Mode of action
- Contra-indications
- Toxicity and drug interactions
- Complications
- Proton pump inhibitors in the treatment of dyspepsia
- Proton pump inhibitors Vs H2 antagonists in oesophagitis
- NICE guidance - management of dyspepsia in adults in primary care (summary section)
- Prevention of peptic ulceration due to NSAIDs
- PPI and glycaemic control
- Proton pump inhibitors (PPIs) in liver cirrhosis
- Proton pump inhibitor (PPI) deprescribing
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.